Phytomenadione (Vitamin K1)Third Party Manufacturing in India

Phytomenadione, also known as Vitamin K1, is a fat-soluble vitamin that is essential for normal blood coagulation. The mechanism of action centers on its role as an essential cofactor for the enzyme gamma-glutamyl carboxylase, which catalyzes the post-translational carboxylation of specific glutamic acid residues to gamma-carboxyglutamic acid residues on vitamin K-dependent proteins. This carboxylation step is critical because it enables these precursor proteins to bind calcium ions and subsequently interact with phospholipid membranes, a prerequisite for their biological activity. The primary vitamin K-dependent coagulation factors synthesized in the liver are Factor II (prothrombin), Factor VII (proconvertin), Factor IX (Christmas factor), and Factor X (Stuart-Prower factor). Two additional vitamin K-dependent proteins with anticoagulant functions are Protein C and Protein S. When vitamin K is deficient or its action is inhibited by anticoagulants such as warfarin or coumarin derivatives, the liver produces biologically inactive precursor forms of these clotting factors because they lack the necessary gamma-carboxyglutamic acid residues. This results in a prolonged prothrombin time and an increased bleeding tendency. Administration of phytomenadione replenishes vitamin K stores, enabling the hepatic gamma-glutamyl carboxylase enzyme to carboxylate and activate the inactive precursor proteins, thereby restoring normal synthesis of functional clotting factors and correcting the coagulopathy. The onset of action after administration is typically 1 to 2 hours, with measurable improvement in prothrombin time.

Therapeutic Uses

Phytomenadione (Vitamin K1) is prescribed for the treatment and prevention of:

• Anticoagulant-Induced Hypoprothrombinemia: Reversal of excessive anticoagulation caused by warfarin, coumarin, or indanedione derivatives. This is the most common indication in adult patients, particularly in emergency settings or before surgery.
• Hemorrhagic Disease of the Newborn: Routine prophylaxis in neonates. A single intramuscular dose of 0.5 to 1 mg within one hour of birth is recommended by the American Academy of Pediatrics to prevent vitamin K deficiency bleeding, a potentially life-threatening condition.
• Vitamin K Deficiency Bleeding: Treatment of bleeding episodes caused by vitamin K deficiency secondary to malabsorption syndromes such as obstructive jaundice, biliary fistula, celiac disease, Crohn's disease, ulcerative colitis, short bowel syndrome, and cystic fibrosis.
• Hypoprothrombinemia Due to Antibacterial Therapy: Correction of vitamin K deficiency caused by broad-spectrum antibiotics that suppress vitamin K-producing gut flora.
• Drug-Induced Hypoprothrombinemia: Reversal of coagulopathy caused by drugs that interfere with vitamin K metabolism, such as salicylates and certain anticonvulsants.
• Liver Disease: Supportive treatment in patients with obstructive liver disease where vitamin K absorption from the gut is impaired due to lack of bile salts.

Why Manufacturers Choose Phytomenadione

Phytomenadione injection 10mg/1ml is a hospital-critical product with consistent institutional demand worldwide. It is a WHO Essential Medicines List item, ensuring government and hospital tenders are a reliable source of demand. Indian manufacturers are well-positioned to serve both the domestic hospital market and export markets in Africa, the Middle East, and Southeast Asia where neonatal vitamin K prophylaxis programs are expanding.

This makes Phytomenadione one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.